Remove Disease Remove Patient Care Remove Pharmaceutical
article thumbnail

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

"But the model that we have is on the opposite end of the spectrum, where the idea is that the theranostics physicians, whether they're nuclear medicine physicians or radiologists, actually temporarily become the patient's subspecialty medical oncologist," Siegel said. "As led by Harshad Kulkarni, MD, as principal investigator.

article thumbnail

GE HealthCare Announces Agreement to Acquire MIM Software

Imaging Technology

Recognizing the industry transformation taking place as digital innovation reshapes the experience of patients and providers, GE HealthCare – a leading global medical technology, pharmaceutical diagnostics, and digital innovator – is focused on developing smart devices, aligned to disease states and enabled by digital.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GE HealthCare Closes MIM Software Acquisition

Imaging Technology

announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. Together, we'll strive to continue our shared legacy of enhancing patient care.

article thumbnail

GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

Imaging Technology

Mark Hibberd, Chief Medical Officer at GE HealthCare’s Pharmaceutical Diagnostics segment, said. Detecting ER+ lesions in patients with recurrent or metastatic breast cancer could potentially aid oncologists, surgeons and clinicians in choosing the most appropriate therapy for patients.”

Clinic 94
article thumbnail

Proscia and Nucleai Partner To Broaden Access To AI Predictive Biomarkers

Imaging Technology

At the center of the collaboration, the companies will integrate Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and make them available as part of Proscia’s precision medicine AI portfolio to better inform patient care. Along with today’s news, Nucleai joins the Proscia Ready partner alliance.

article thumbnail

AI Where It Makes a Difference: ACC’s CIO Talks Cardiovascular Innovation

Aidoc

Cardiovascular care has seen remarkable advancements over the decades, from innovative surgical techniques to cutting-edge pharmaceuticals. Despite these strides, treatment pathways are often plagued by inefficiencies, administrative burdens and even care disparities. Yet, challenges remain.

IT 52
article thumbnail

AuntMinnie 2007: Gadolinium: A 'necessary factor' in the development of NSF?

AuntMinnie

Imagine going in for a diagnostic MRI scan and coming out with a progressive, irreversible, and potentially fatal disease. That's what has happened to hundreds of people worldwide who have developed nephrogenic systemic fibrosis (NSF), an acquired disorder in renal patients that's been classified only since 2000. In 2006 the U.S.

Disease 290